Provided by Tiger Trade Technology Pte. Ltd.

Protagonist Therapeutics

146.08
-0.4100-0.28%
Post-market: 146.300.2200+0.15%19:09 EDT
Volume:561.61K
Turnover:82.10M
Market Cap:9.45B
PE:141.83
High:149.42
Open:148.00
Low:144.61
Close:146.49
52wk High:160.81
52wk Low:54.50
Shares:64.71M
Float Shares:63.17M
Volume Ratio:1.21
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.03
EPS(LYR):-2.0500
ROE:10.98%
ROA:4.55%
PB:11.23
PE(LYR):-71.26

Loading ...

Protagonist Therapeutics (PTGX) Is Up 6.3% After Swing To Q2 Profitability And ESOP Usage Shift

Simply Wall St.
·
Aug 17

Protagonist Therapeutics CEO Dinesh V. Patel Disposes of USD 14.89 Million in Common Shares

Reuters
·
Aug 13

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

MT Newswires Live
·
Aug 11

Protagonist Therapeutics Price Target Raised to $170.00/Share from $145.00 by Truist Securities

Dow Jones
·
Aug 11

Silence Therapeutics Jumps After Mid-Stage Trial Data for Blood Cancer Drug

Reuters
·
Aug 11

Protagonist Therapeutics price target raised to $170 from $145 at Truist

TIPRANKS
·
Aug 10

Protagonist Therapeutics (PTGX) Receives a Buy from Wedbush

TIPRANKS
·
Aug 10

Truist Adjusts Price Target on Protagonist Therapeutics to $170 From $145, Maintains Buy Rating

MT Newswires Live
·
Aug 10

Protagonist Therapeutics, Inc. : JP Morgan Raises Target Price to $149 from $113

THOMSON REUTERS
·
Aug 10

Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND), Protagonist Therapeutics (PTGX) and Zoetis (ZTS)

TIPRANKS
·
Aug 07

Protagonist Therapeutics price target raised to $153 from $151 at Barclays

TIPRANKS
·
Aug 06

Protagonist Therapeutics, Inc. : Leerink Partners Raises Target Price to $150.00 from $110.00

THOMSON REUTERS
·
Aug 06

Protagonist Therapeutics reports Q2 EPS $2.29, consensus $1.93

TIPRANKS
·
Aug 06

Protagonist Therapeutics Q2 EPS $2.29 Beats $1.66 Estimate, Sales $213.475M Beat $203.764M Estimate

Benzinga Earnings
·
Aug 06

Protagonist Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Protagonist Returns to Profit in Q2 FY26 with Net Income of $162.85 Million

Reuters
·
Aug 06

PTGX’s PN-881 Phase 1 Completion: A Quiet Milestone With Big Pipeline Implications

TIPRANKS
·
Aug 06

Protagonist Therapeutics Grants New Hires Options for 7,300 Shares, RSUs for 1,975 Shares at $136.64 Strike Price

Reuters
·
Aug 05

Protagonist Therapeutics (PTGX) Stock Looks Stretched As A Price Target Boost Lands

Simply Wall St.
·
Jul 25

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), UnitedHealth (UNH) and AnaptysBio (ANAB)

TIPRANKS
·
Jul 22